Why the study?
Does discontinuation of β-blockers beyond 1 year after AMI increase the risk of death or readmission for ACS in revascularized patients without heart failure?
Does discontinuation of β-blockers beyond 1 year after AMI increase the risk of death or readmission for ACS in revascularized patients without heart failure?
Discontinuing beta-blockers beyond 1 year after AMI in revascularized patients without heart failure may increase the risk of death or ACS readmission.
Answers are grounded in this paper and cite their sources.
May warrant caution discontinuing β-blockers beyond 1 year post-AMI in revascularized patients without HF; leaves open need for RCTs to confirm.
In routine care of patients without heart failure, revascularized and optimally treated after AMI, discontinuation of β-blockers beyond 1 year after AMI was associated with an increased risk of death or readmission for ACS, while statistical significance was not reached for the association with all-cause mortality. A contemporary randomized clinical trial is needed to precise the role of β-blockers in the long-term treatment after AMI.
No takes yet. Share an insight, caveat, or question.
Neumann et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: